Welcome to our dedicated page for Harrow news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow stock.
Harrow Health, Inc. (NASDAQ: HROW) is a leading eyecare pharmaceutical company dedicated to developing, producing, and distributing medications that address unmet medical needs, primarily within the United States. The company’s core business revolves around the creation of ophthalmology-based formulations, providing both sterile and non-sterile compounded medications to physicians and patients.
Harrow Inc. is at the forefront of innovative therapeutics, focusing on the treatment of ocular surface diseases. The firm's product portfolio includes prominent drug candidates such as SURF-100 and SURF-200, which are topical eye drops; SURF-300, an oral capsule aimed at treating ocular surface diseases and dry eye disease (DED) symptoms; and Klarity drops, designed for the protection and rehabilitation of ocular surface pathology in DED patients.
Additionally, Harrow, Inc. is known for its non-intravenous sedation and anesthesia products for various medical procedures. MELT-100, for instance, is a sublingual drug facilitating conscious sedation during cataract surgery, and MAY-66 is utilized for alleviating symptoms associated with Peyronie’s disease.
Harrow Health's commitment goes beyond innovation; it strives to improve accessibility and affordability of eyecare pharmaceuticals for millions of Americans. Through strategic partnerships and ongoing projects, Harrow, Inc. continues to enhance its capabilities in the eyecare sector, firmly positioning itself as a trusted name among U.S. eyecare professionals.
Stay updated with the latest developments, financial reports, and news on Harrow, Inc. to understand how this company is shaping the future of ophthalmic care.
Harrow Health, Inc. (Nasdaq: HROW) announced that the FDA has accepted its New Drug Application (NDA) for AMP-100, aimed at ocular surface anesthesia. The application has a PDUFA date of October 16, 2022.
CEO Mark L. Baum emphasized that if approved, AMP-100 would be the first non-opioid ophthalmic drug of its kind in the U.S. Harrow Health is committed to making this innovative drug commercially available to ophthalmologists and surgery centers nationwide.
Harrow Health, Inc. (NASDAQ: HROW), a healthcare company focused on ophthalmology, announced that CEO Mark L. Baum and CFO Andrew Boll will present at the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Their presentation is scheduled for February 24, 2022, at 3:30 p.m. ET. To view the presentation, attendees can access the link on Harrow Health's website in the events section. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (NASDAQ: HROW) has released its inaugural 2022 Corporate Transparency Report, emphasizing its commitment to making sight-saving medications accessible. CEO Mark L. Baum highlights sustainable business practices aimed at benefiting customers and communities. The report details the company’s dedication to innovation, quality, and ethical standards while maintaining strong corporate governance. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in affiliated companies. The report is available in the Investors section of the company’s website.
NASHVILLE, Tenn. -- Harrow Health (NASDAQ: HROW) announced participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations website starting January 10 at 7:00 a.m. ET, remaining accessible for 90 days. Harrow Health specializes in ophthalmic healthcare and operates ImprimisRx and Visionology, focusing on innovative eye care solutions.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Harrow Health (NASDAQ: HROW) announced the acquisition of U.S. commercialization rights for four FDA-approved ophthalmic medications from Novartis for $14 million. The products include IOPIDINE®, MAXITROL®, and MOXEZA®, which will enhance Harrow's portfolio in the ophthalmic surgical and acute care markets. This acquisition positions Harrow as a unique provider of both branded products and compounded formulations in the U.S. market, leveraging its ImprimisRx platform for distribution.
Harrow Health, Inc. (Nasdaq: HROW) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective December 20, 2021. This inclusion is a recognition of the company's performance among biotechnology and pharmaceutical securities. CEO Mark L. Baum expressed pride in this milestone, viewing it as validation of the team's efforts to create value for stakeholders. Harrow Health focuses on ophthalmic healthcare, operating ImprimisRx and Visionology, and has interests in other pharmaceuticals. The company aims to provide innovative and affordable eye care solutions.
Harrow Health reports record revenues of $18.7 million for Q3 2021, marking a 30% increase from $14.4 million in the same period last year. The company maintains a gross margin of 74% and achieved commissions from DEXYCU® sales of $900,000. Harrow acquired two FDA drug candidates, AMP-100 and MAQ-100, aiming to enhance its product offerings. Cash and cash equivalents stood at $57.9 million as of September 30, 2021. CEO Mark L. Baum emphasized strong revenue growth, despite challenges posed by COVID-19.
Harrow Health, Inc. (NASDAQ: HROW) will release its third-quarter financial results for 2021 on
Harrow Health, Inc. (NASDAQ: HROW) announced a $13.5 million senior secured loan to Melt Pharmaceuticals, Inc. to support the Phase 2 study of its lead drug candidate MELT-300, aimed at providing a non-opioid solution for sedation during cataract surgery. Melt plans to dose the first patient in
FAQ
What is the current stock price of Harrow (HROW)?
What is the market cap of Harrow (HROW)?
What does Harrow, Inc. specialize in?
What are some key products of Harrow, Inc.?
What is the significance of SURF-300?
How does MELT-100 benefit patients?
Who are the primary customers of Harrow, Inc.?
What makes Harrow, Inc. unique in the eyecare pharmaceutical sector?
How does Harrow, Inc. contribute to the treatment of dry eye disease (DED)?
Where is Harrow, Inc. based?
What recent achievements has Harrow, Inc. made?
How can investors stay updated with Harrow, Inc.'s latest news?
